Skip to main content

Table 1 Baseline characteristics

From: Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial

Items TOCE TOCE + HAIC Provability
n = 9 n = 10
Age (years) Median 81 72 0.22
Range 55–85 36–84
Gender Female 2 5 0.09
Male 7 5
Performance status 0/1 8/1 10/0 0.47
Etiology HBV infection 1 1 0.32
HCV infection 7 5
Alcohol 0 1
NASH 0 1
Autoimmune hepatitis 0 1
Primary Biliary Cirrhosis 0 1
Unknown Etiology 1 0
Cirrhosis (Yes/No)   9/0 10/0 1.00
Child-Pugh Grade A/B/C 8/1/0 7/3/0 0.36
Size (mm) Median 22 21.5 0.87
Range 10–32 10–85
Number 1 0 1 0.41
≤3 4 1
>3 5 8
TNM I/II/III 0/3/6 0/5/5 0.55
BCLC 0/A/B/C/D 0/3/6/0/0 0/2/8/0/0 0.65
Previous Treatment DDP-H 8 7  
TACE 9 6 0.51
  1. TOCE, transarterial oily chemoembolization; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; NASH, non-alcoholic steatohepatitis; BCLC, Barcelona-Clinic Liver Cancer staging classification